Showing 1411-1420 of 7509 results for "".
Taylor Made: One-of-a-kind Solutions for Device-based Services
https://practicaldermatology.com/topics/practice-management/taylor-made-one-of-a-kind-solutions-for-device-based-services/18789/An expert on the leading edge of device-based interventions, Mark B. Taylor, MD has learned when and how to adopt technologies and how to get the most from the systems in his practice. In this edition of Best Practices in Aesthetics, host Joel L. Cohen, MD asks Dr. Taylor to share his tips for optimNew Treatment Algorithms for Actinic Keratoses
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-treatment-algorithms-for-actinic-keratoses/18812/Gary Goldenberg, MD reviews the literature showing why all actinic keratoses (AKs) need to be treated and why it's important to treat the field and not just the visible lesions. He shares his evidence-based, time-sequential therapy approach to combining a destructive modality with field therapy to pLong-Term Effects of Neuromodulators on Aging
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/long-term-effects-of-neuromodulators-on-aging/18810/Shannon Humphrey, MD discusses the cumulative anti-aging benefits of long-term treatments with botulinum toxin type A. She shares her observations from the bench and offers a review of what the literature shows to support her recommendation for regular conservative neuromodulator treatments to improAdvances in Devices for Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/advances-in-devices-for-dermatology/18815/M. Christine Lee, MD provides an overview of some of the new and emerging laser technologies. She discusses advances in everything from lasers and light-based devices to radiofrequency, ultrasound, and combination devices for a variety of dermatologic issues including facial rejuvenation, vaginal reThe Complex World of Biosimilars
https://practicaldermatology.com/topics/psoriasis/the-complex-world-of-biosimilars/18633/Jashin Wu, MD, discusses potential concerns with biosimilars, including the chance of inducing variable immunogenic responses compared with reference agents. Although there are currently no biosimilars approved for use in psoriasis in the United States, these agents are fast approaching market availThe Evolving Paradigm in Treatment of Psoriasis
https://practicaldermatology.com/topics/psoriasis/the-evolving-paradigm-in-treatment-of-psoriasis/18640/Bruce Strober, MD, reviews the latest science in the management of psoriasis. Treatment strategies on the horizon may offer significantly improved efficacy with attractive dosing schedules, adding to the ability to help patients manage difficult skin and systemic implications of psoriasis, he said.Valeant Business Update; Melanoma Drugs Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-business-update-melanoma-drugs-approved/18679/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, we take a look at Valeant's warning of disruption of dermatology business following its break from specialty pharmacy Philidor. Plus, an update on Melanoma Therapeutics, including approvals of ImlygicTopical Treatment Considerations for Psoriasis
https://practicaldermatology.com/topics/psoriasis/topical-treatment-considerations-for-psoriasis/18845/Jerry Bagel, MD and Neil J. Korman, MD discuss topical treatment options for treating patients with mild psoriasis. They share insights about the effect of vehicles on compliance, particularly when treating patients with scalp psoriasis.Aging: The Cornerstone of Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/aging-the-cornerstone-of-dermatology/18865/In this edition of Derm Insider, Joseph Jorizzo, MD, Brooke Jackson, MD, and Adam Friedman, MD sit down with host Neal Bhatia, MD to discuss the phenomenon of aging and the ubiquitous role it plays in both the scientific and clinical practice of dermatology. In particular they reflect on the evolutiEpiduo Forte Approved; Facial Aesthetics By Age
https://practicaldermatology.com/topics/practice-management/dermwiretv-epiduo-forte-approved-facial-aesthetics-by-age/18870/Galderma's non-antibiotic Epiduo Forte (Adapalene 0.3% and benzoyl peroxide 2.5%) approved for topical management of acne vulgaris. Trends reveal differences in women's facial cosmetic surgery by age. AMA and CMS offer ICD-10 help. Plus: An Update on NewDerm LIVE.